Cytokines in equine platelet lysate and related blood products.
Authors: Moellerberndt Julia, Hagen Alina, Niebert Sabine, Büttner Kathrin, Burk Janina
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Cytokines in Equine Platelet Lysate and Related Blood Products Platelet lysate (PL) is increasingly used in equine regenerative medicine both as a direct therapeutic agent and as a culture supplement for mesenchymal stromal cells, yet understanding of its bioactive components remains limited. Moellerberndt and colleagues analysed six key cytokines (interleukins 1β, 4, 6 and 10, interferon-γ and tumour necrosis factor-α) across serum, plasma, platelet concentrate and PL samples from 20 clinically healthy horses, using sandwich ELISAs to quantify concentrations and correlate findings with blood chemistry parameters. Whilst cytokine levels remained consistent across the different blood product stages, the study revealed striking inter-individual variability—some horses produced blood products with extremely high cytokine concentrations whilst others had undetectable levels—alongside a significant association between elevated cytokines and abnormal blood chemistry findings. These results carry important implications for clinical practice: the therapeutic efficacy of PL may vary substantially between donor horses depending on their individual cytokine profiles, meaning standardised dosing approaches may not account for profound differences in anti-inflammatory versus pro-inflammatory bioactivity. Practitioners using PL should consider that routine blood chemistry screening could help predict the immunomodulatory potential of a given product, potentially guiding selection of appropriate donors or treatment protocols in both therapeutic and laboratory applications.
Read the full abstract on PubMed
Practical Takeaways
- •Donor horse selection and blood chemistry screening should be performed before harvesting platelet lysate for therapy or cell culture, as cytokine content varies dramatically between individuals and affects therapeutic efficacy.
- •Platelet lysate from horses with abnormal blood chemistry may have substantially different anti- or pro-inflammatory properties, potentially altering clinical outcomes in regenerative medicine applications.
- •Consider baseline bloodwork as part of the platelet lysate production protocol to predict and standardize the immunomodulatory properties of the final product.
Key Findings
- •Cytokine concentrations (IL-1β, IL-4, IL-6, IL-10, IFN-γ, TNF-α) in serum, plasma, platelet concentrate, and platelet lysate were similar and correlated significantly across all sample types.
- •Large inter-individual variability in cytokine concentrations was observed between donor horses, with some donors producing very high concentrations while others had no measurable cytokine content.
- •Horses with abnormal blood chemistry findings had significantly higher cytokine concentrations in their blood products compared to clinically normal horses.
- •Blood chemistry analysis may be a useful predictor of cytokine concentrations in platelet-based products for therapeutic and culture applications.